We provide you with 20 years of free, institutional-grade data for IPHA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of IPHA. Explore the full financial landscape of IPHA stock.
| Reported Date | CIK | Ticker | Type |
|---|
Innate Pharma S.A(NASDAQ:IPHA) 
Innate Pharma S.A., a biotechnology company, discovers and develops therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tu...
Website: http://www.innate-pharma.com/en
Founded: 1999
IPO Price: $5.5 (Oct 17, 2019)
Full Time Employees: 247
CEO: Mondher Mahjoubi
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about IPHA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.